Alternative scheduling of pulsatile, high dose sunitinib efficiently suppresses tumor growth

BACKGROUND: Increased exposure to multitargeted kinase inhibitor sunitinib is associated with improved outcome, emphasizing the importance of maintaining adequate dosing and drug levels. The currently approved schedule (50 mg daily, four weeks on, two weeks off) precludes further dose-intensificatio...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:J Exp Clin Cancer Res
Main Authors: Rovithi, Maria, de Haas, Richard R., Honeywell, Richard J., Poel, Dennis, Peters, Godefridus J., Griffioen, Arjan W., Verheul, Henk M. W.
Format: Artigo
Sprog:Inglês
Udgivet: BioMed Central 2016
Fag:
Research
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5013589/
https://ncbi.nlm.nih.gov/pubmed/27604186
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13046-016-0411-2
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker